[go: up one dir, main page]

WO2004082589A3 - Nasally administrable, bioavailable pharmaceutical composition of loratadine - Google Patents

Nasally administrable, bioavailable pharmaceutical composition of loratadine Download PDF

Info

Publication number
WO2004082589A3
WO2004082589A3 PCT/IB2004/000839 IB2004000839W WO2004082589A3 WO 2004082589 A3 WO2004082589 A3 WO 2004082589A3 IB 2004000839 W IB2004000839 W IB 2004000839W WO 2004082589 A3 WO2004082589 A3 WO 2004082589A3
Authority
WO
WIPO (PCT)
Prior art keywords
loratadine
pharmaceutical composition
nasally administrable
bioavailable pharmaceutical
bioavailable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/000839
Other languages
French (fr)
Other versions
WO2004082589A2 (en
Inventor
Ashish Sehgal
Jyoti Srivastava
Vinod Kumar Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2004082589A2 publication Critical patent/WO2004082589A2/en
Publication of WO2004082589A3 publication Critical patent/WO2004082589A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to nasally administrable, bioavailable pharmaceutical compositions of loratadine for the treatment of allergic rhinitis and processes for their preparation. These formulations include a solid dispersion of loratadine with a carrier in an aqueous vehicle and provide the same bioavailability as an oral dosage form at reduced dose.
PCT/IB2004/000839 2003-03-20 2004-03-22 Nasally administrable, bioavailable pharmaceutical composition of loratadine Ceased WO2004082589A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN321/DEL/2003 2003-03-20
IN321DE2003 2003-03-20
IN320/DEL/2003 2003-03-20
IN320DE2003 2003-03-20

Publications (2)

Publication Number Publication Date
WO2004082589A2 WO2004082589A2 (en) 2004-09-30
WO2004082589A3 true WO2004082589A3 (en) 2004-11-04

Family

ID=33031490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000839 Ceased WO2004082589A2 (en) 2003-03-20 2004-03-22 Nasally administrable, bioavailable pharmaceutical composition of loratadine

Country Status (1)

Country Link
WO (1) WO2004082589A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809322B2 (en) 2007-01-19 2014-08-19 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465746B (en) 2008-11-21 2011-02-16 Fortune Apex Dev Ltd Pharmaceutical composition for topical application
CN106138990B (en) * 2015-04-16 2020-01-10 贵州益佰女子大药厂有限责任公司 Rupikang solid dispersion preparation and preparation method thereof
CN119214988B (en) * 2024-11-29 2025-03-07 博济医药科技股份有限公司 Nasal administration preparation for treating rhinitis, preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A2 (en) * 1994-09-28 1996-05-01 Senju Pharmaceutical Co., Ltd. An aqueous nasal suspension comprising cyclodextrin
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A2 (en) * 1994-09-28 1996-05-01 Senju Pharmaceutical Co., Ltd. An aqueous nasal suspension comprising cyclodextrin
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809322B2 (en) 2007-01-19 2014-08-19 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US9289432B2 (en) 2007-01-19 2016-03-22 HANANJA EHF and UNIVERSITY OF ICELAND Methods and compositions for the delivery of a therapeutic agent

Also Published As

Publication number Publication date
WO2004082589A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
GB0428475D0 (en) Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
IL178822A (en) 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
WO2006087543A8 (en) Antibacterial piperidine derivatives
EE05404B1 (en) A quinuclidine derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
EP1521749B8 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
PL371853A1 (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
PL372998A1 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
UA105078C2 (en) Pharmaceutical composition containing tetrahydrofolic acid
YU58103A (en) Pharmaceutical dosage forms of epothilones for oral administration
WO2000072837A3 (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
IL179611A (en) 1-aza-bicycloalkyl derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for the treatment of psychotic disorders
IL189270A (en) Phosphonated rifamycins and derivatives thereof, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for the prevention and treatment of bone and joint infections
WO2007113202A8 (en) Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2005053727A3 (en) Pharmaceutical compositions for bioactive peptide agents
WO2005055939A3 (en) Vinca derivatives
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
WO2004082589A3 (en) Nasally administrable, bioavailable pharmaceutical composition of loratadine
WO2008033930A3 (en) Vinca derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 4769/DELNP/2005

Country of ref document: IN

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase